Prognostic Values of Various Clinical Factors and Genetic Subtypes for Diffuse Large B-cell lymphoma Patients: A Retrospective Analysis of 227 Cases

Zhou, De; Xie, Wan-Zhuo; Hu, Ke-Yue; Huang, Wei-Jia; Wei, Guo-Qing; He, Jing-Song; Shi, Ji-Min; Luo, Yi; Li, Li; Zhu, Jing-Jing; Zhang, Jie; Lin, Mao-Fang; Ye, Xiu-Jin; Cai, Zhen; Huang, He

추천

검색

자료유형: 학술저널

저자정보: Zhou, De (Department of Hematology, Bone Marrow Transplant Center, the First Affiliated Hospital of Medical School of Zhejiang University) Xie, Wan-Zhuo (Department of Hematology, Bone Marrow Transplant Center, the First Affiliated Hospital of Medical School of Zhejiang University) Hu, Ke-Yue (Department of Hematology, Bone Marrow Transplant Center, the First Affiliated Hospital of Medical School of Zhejiang University) Huang, Wei-Jia (Department of Hematology, Bone Marrow Transplant Center, the First Affiliated Hospital of Medical School of Zhejiang University) Wei, Guo-Qing (Department of Hematology, Bone Marrow Transplant Center, the First Affiliated Hospital of Medical School of Zhejiang University) He, Jing-Song (Department of Hematology, Bone Marrow Transplant Center, the First Affiliated Hospital of Medical School of Zhejiang University) Shi, Ji-Min (Department of Hematology, Bone Marrow Transplant Center, the First Affiliated Hospital of Medical School of Zhejiang University) Luo, Yi (Department of Hematology, Bone Marrow Transplant Center, the First Affiliated Hospital of) Li, Li Zhu, Jing-Jing Zhang, Jie Lin, Mao-Fang Ye, Xiu-Jin Cai, Zhen Huang, He

저널정보: 아시아태평양암예방학회 Asian Pacific journal of cancer prevention : APJCP Asian Pacific journal of cancer prevention : APJCP 제14권 제2호

발행연도: 2013.1

수록면: 929 - 934 (6page)

이용수

📌

연구주제

📖

연구배경

🔬

연구방법

🏆

연구결과

초록· 키워드

오류제보하기

Aim: To analyze the significance of different clinical factors for prognostic prediction in diffuse large B-cell lymphoma (DLBCL) patients. Methods: Two hundred and twenty-seven DLBCL patients were retrospectively reviewed. Patients were managed with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) regimen or rituximab plus the CHOP (RCHOP) regimen. Results: Lactate dehydrogenase (LDH), ${\beta}2$-microglobulin (${\beta}2$-M), B symptoms, Ann Arbor stage and genetic subtypes were statistically relevant in predicting the prognosis of the overall survival (OS). In the CHOP group, the OS in patients with germinal center B-cell-like (GCB)(76.2%) was significantly higher than that of the non-GCB group (51.9%, P=0.032). With RCHOP management, there was no statistical difference in OS between the GCB (88.4%) and non-GCB groups (81.9%, P=0.288). Conclusion: Elevated LDH and ${\beta}2$-M levels, positive B symptoms, Ann Arbor stage III/IV, and primary nodal lymphoma indicate an unfavorable prognosis of DLBCL patients. Patients with GCB-like DLBCL have a better prognosis than those with non-GCB when treated with the CHOP regimen. The RCHOP treatment with the addition of rituximab can improve the prognosis of patients with DLBCL.

#Diffuse large B-cell lymphoma #prognostic analysis #genetic subtypes #rituximab #overall survival

참고문헌 (0)

참고문헌 신청

참고문헌이 DBpia에서 서비스 중이라면, [참고문헌 신청]을 통해 등록해보세요

이 논문의 저자 정보

Zhou, De

소속기관 Department of Hematology, Bone Marrow Transplant Center, the First Affiliated Hospital of Medical Sc